References
- Beral V., Million Women Study Collaborators. Ovarian cancer and hormone replacement therapy in the Million Women Study. The Lancet 2007; 369: 1703–1710
- Neves-e-Castro M. Why do some breast cancer cells remain dormant?. Gynecol Endocrinol 2006; 22: 190–197
- Meltzer A. Dormancy and breast cancer. J Surg Oncol 1990; 43: 181–188
- Wong A S, Leung P C. Role of endocrine and growth factors on the ovarian surface epithelium. J Obstet Gynaecol Res 2007; 33: 3–16
- Juengel J L, Heath D A, Quirke L D, McNatty K P. Oestrogen receptor α and β, androgen receptor and progesterone receptor mRNA and protein localisation within the developing ovary and in small growing follicles of sheep. Reproduction 2006; 131: 81–92
- D'Haeseleer M, Van Poucke M, Van den Broeck W. Cell-specific localization of oestrogen receptor β (ESR2) mRNA within various bovine ovarian cell types using in situ hybridization. Anat Histol Embryol 2005; 34: 265–272
- Buckanovich R J, Sasaroli D, O'Brien-Jenkins A, Botbyl J, Hammond R, Katsaros D, Sandaltzopoulos R, Liotta L A, Gimotty P A, Coukos G. Tumor vascular proteins as biomarkers in ovarian cancer. J Clin Oncol 2007; 25: 852–861
- Nielsen M, Thomsen J L, Primdahl S, Dyreborg U, Andersen J A. Breast cancer and atypia among young and middle-aged women: a study of 110 medicolegal autopsies. Br J Cancer 1987; 56: 814–819
- Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002; 288: 321–333
- Grodstein F, Manson J E, Colditz G A, Willett W C, Speizer F E, Stampfer M J. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000; 133: 933–941
- Lacey J V, Brinton L A, Leitzmann M F, Mouw T, Hollenbeck A, Schatzkin A, Hartge P. Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health–AARP Diet and Health Study Cohort. J Natl Cancer Inst 2006; 98: 1397–1405
- Beehler G P, Sekhon M, Baker J A, Teter B E, McCann S E, Rodabaugh K J, Moysich K B. Risk of ovarian cancer associated with BMI varies by menopausal status. J Nutr 2006; 136: 2281–2286
- Yang C Y, Kuo H W, Chiu H F. Age at first birth, parity, and risk of death from ovarian cancer in Taiwan: a country of low incidence of ovarian cancer. Int J Gynecol Cancer 2007; 17: 32–36
- Olsen C M, Green A C, Whiteman D C, Sadeghi S, Kolahdooz F, Webb P M. Obesity and the risk of epithelial ovarian cancer: a systematic review and meta-analysis. Eur J Cancer 2007; 43: 690–709
- Jordan S J, Whiteman D C, Purdie D M, Green A C, Webb P M. Does smoking increase risk of ovarian cancer? A systematic review. Gynecol Oncol 2006; 103: 1122–1129
- Peterson N B, Trentham-Dietz A, Newcomb P A, Chen Z, Hampton J M, Willett W C, Egan K M. Alcohol consumption and ovarian cancer risk in a population-based case–control study. Int J Cancer 2006; 119: 2423–2427
- Rossing M A, Tang M T, Flagg E W, Weiss L K, Wicklund K G, Weiss N S. Body size and risk of epithelial ovarian cancer (United States). Cancer Causes Control 2006; 17: 713–720
- Greer J B, Modugno F, Ness R B, Allen G O. Anthropometry and the risk of epithelial ovarian cancer. Cancer 2006; 106: 2247–2257
- Baker J A, Odunuga O O, Rodabaugh K J, Reid M E, Menezes R J, Moysich K B. Active and passive smoking and risk of ovarian cancer. Int J Gynecol Cancer 2006; 16(Suppl 1)211–218
- Patel A V, Rodriguez C, Pavluck A L, Thun M J, Calle E E. Recreational physical activity and sedentary behavior in relation to ovarian cancer risk in a large cohort of US women. Am J Epidemiol 2006; 163: 709–716
- Abenhaim H A, Titus-Ernstoff L, Cramer D W. Ovarian cancer risk in relation to medical visits, pelvic examinations and type of health care provider. Can Med Assoc J 2007; 176: 941–947